RO7795081
Sponsors
F. Hoffmann-La Roche AG, Hoffmann-La Roche
Conditions
Healthy ParticipantsHealthy VolunteersObesityObesity or OverweightOverweightOverweight or ObesityType 2 Diabetes MellitusType 2 Diabetes Mellitus (T2D)
Phase 1
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
CompletedNCT06809608
Start: 2025-02-13End: 2025-06-16Updated: 2025-07-08
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
RecruitingNCT06982131
Start: 2025-06-04End: 2026-12-04Target: 40Updated: 2026-03-06
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Not yet recruitingNCT07499050
Start: 2026-03-31End: 2026-12-29Target: 30Updated: 2026-03-30
Phase 2
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
Active, not recruitingNCT07081958
Start: 2025-07-29End: 2026-07-17Target: 340Updated: 2026-01-15
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RecruitingNCT07112872
Start: 2025-08-19End: 2027-02-08Target: 240Updated: 2026-03-12
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus
RecruitingCTIS2024-520322-11-00
Start: 2025-09-29Target: 74Updated: 2025-09-08